Form 4: Amneal CFO Sells Nearly 500K Shares

Amneal Pharmaceuticals' CFO, Tasos Konidaris, sold nearly 500,000 shares of Class A Common Stock over three days in August 2025, reducing his direct holdings.

Summary

• Tasos Konidaris, Executive Vice President & CFO of Amneal Pharmaceuticals, Inc. (AMRX), reported the sale of 499,730 shares of Class A Common Stock.
• The sales occurred over three consecutive days: August 13, 2025, August 14, 2025, and August 15, 2025.
• On August 13, 2025, 161,365 shares were sold at a weighted average price of $9.22 per share, with prices ranging from $9.12 to $9.40.
• On August 14, 2025, 119,206 shares were sold at a weighted average price of $9.30 per share, with prices ranging from $9.25 to $9.34.
• On August 15, 2025, 219,159 shares were sold at a weighted average price of $9.43 per share, with prices ranging from $9.40 to $9.47.
• Following these transactions, Mr. Konidaris directly beneficially owns 122,152 shares of Class A Common Stock.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to a significant insider sale by a key executive, even though it was pre-planned under a 10b5-1 arrangement. Such sales can reduce investor confidence and signal a belief that the stock is fully valued.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on new, non-public information.

Negatives

• A significant reduction in direct beneficial ownership by a key executive (CFO) can be perceived as a negative signal regarding management's confidence in the company's near-term stock performance or valuation.
• The total sale of 499,730 shares represents a substantial portion of the executive's previous holdings, reducing insider alignment.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing reports an insider transaction and does not provide information related to broader industry trends or competitors.

Stakeholder Impact

• Shareholders may perceive a reduction in management's alignment with shareholder interests due to the significant decrease in the CFO's direct stock holdings.
• The market might interpret the sale as a signal of limited upside potential or a belief that the stock is adequately valued by the executive.

Key Dates

Recommendation

While the insider sale was pre-planned under a 10b5-1 arrangement, the substantial volume of shares sold by the CFO could be interpreted as a signal that the executive views the stock as fully valued or has personal liquidity needs. This action, while not necessarily indicative of negative company performance, does not provide a strong positive catalyst for the stock. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor future company performance and insider activity before making further investment decisions.

Keywords

Amneal Pharmaceuticals, AMRX, insider trading, Form 4, stock sale, CFO, Tasos Konidaris, 10b5-1 plan